The estimated Net Worth of Nitin Sood is at least $1.63 million dollars as of 7 August 2023. Nitin Sood owns over 16,202 units of Adaptive Biotechnologies stock worth over $943,007 and over the last 3 years Nitin sold ADPT stock worth over $689,886.
Nitin has made over 4 trades of the Adaptive Biotechnologies stock since 2022, according to the Form 4 filled with the SEC. Most recently Nitin sold 16,202 units of ADPT stock worth $107,257 on 7 August 2023.
The largest trade Nitin's ever made was selling 31,066 units of Adaptive Biotechnologies stock on 1 November 2022 worth over $248,528. On average, Nitin trades about 13,547 units every 61 days since 2021. As of 7 August 2023 Nitin still owns at least 214,808 units of Adaptive Biotechnologies stock.
You can see the complete history of Nitin Sood stock trades at the bottom of the page.
Nitin's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.
Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... et Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies executives and other stock owners filed with the SEC include: